Document Detail


N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells.
MedLine Citation:
PMID:  19295615     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A magnetite nanoparticle, NPrCAP/M, was produced for intracellular hyperthermia treatment of melanoma by conjugating N-propionyl-cysteaminylphenol (NPrCAP) with magnetite and used for the study of selective targeting and degradation of melanoma cells. NPrCAP/M, like NPrCAP, was integrated as a substrate in the oxidative reaction by mushroom tyrosinase. Melanoma, but not non-melanoma, cells incorporated larger amounts of iron than magnetite from NPrCAP/M. When mice bearing a B16F1 melanoma and a lymphoma on opposite flanks were given NPrCAP/M, iron was observed only in B16F1 melanoma cells and iron particles (NPrCAP/M) were identified within late-stage melanosomes by electron microscopy. When cells were treated with NPrCAP/M or magnetite and heated to 43 degrees C by an external alternating magnetic field (AMF), melanoma cells were degraded 1.7- to 5.4-fold more significantly by NPrCAP/M than by magnetite. Growth of transplanted B16 melanoma was suppressed effectively by NPrCAP/M-mediated hyperthermia, suggesting a clinical application of NPrCAP/M to lesional therapy for melanoma. Finally, melanoma cells treated with NPrCAP/M plus AMF showed little sub-G1 fraction and no caspase 3 activation, suggesting that the NPrCAP/M-mediated hyperthermia induced non-apoptotic cell death. These results suggest that NPrCAP/M may be useful in targeted therapy for melanoma by inducing non-apoptotic cell death after appropriate heating by the AMF.
Authors:
Makito Sato; Toshiharu Yamashita; Masae Ohkura; Yasue Osai; Akiko Sato; Tomoaki Takada; Hidenobu Matsusaka; Ichiro Ono; Yasuaki Tamura; Noriyuki Sato; Yasushi Sasaki; Akira Ito; Hiroyuki Honda; Kazumasa Wakamatsu; Shosuke Ito; Kowichi Jimbow
Related Documents :
17448195 - Cutaneous clear-cell granular cell tumors: the histologic description of an unusual var...
1363425 - Dysplastic nevus syndrome: melanoma-prone disease.
8568005 - Clear cell adenocarcinoma of the colon.
3396005 - Effects of folate deficiency on the metastatic potential of murine melanoma cells.
21552385 - Cellular and phenotypic characterization of canine osteosarcoma cell lines.
10338535 - Macrophages and epithelial cells respond differently to the pseudomonas aeruginosa type...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-03-19
Journal Detail:
Title:  The Journal of investigative dermatology     Volume:  129     ISSN:  1523-1747     ISO Abbreviation:  J. Invest. Dermatol.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-10-07     Completed Date:  2009-10-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0426720     Medline TA:  J Invest Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2233-41     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Sapporo Medical University, Sapporo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Line, Tumor
Cell Survival
Cystamine / analogs & derivatives*,  metabolism,  pharmacology
Female
Ferrosoferric Oxide / metabolism,  pharmacology*
Humans
Hyperthermia, Induced
Magnetics
Melanoma, Experimental / drug therapy*,  pathology
Mice
Mice, Inbred C57BL
Monophenol Monooxygenase / metabolism
Nanoparticles*
Phenols / metabolism,  pharmacology*
Chemical
Reg. No./Substance:
0/N-propionyl-4-S-cysteaminylphenol; 0/Phenols; 1317-61-9/Ferrosoferric Oxide; 51-85-4/Cystamine; EC 1.14.18.1/Monophenol Monooxygenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for ps...
Next Document:  Differential effects of corticosteroids and pimecrolimus on the developing skin immune system in hum...